The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma

Abstract

IntroductionThe combination of platelet count and neutrophil to lymphocyte ratio (COP-NLR) has been shown to provide prognostic information in several cancers, whereas its prognostic value in renal cell carcinoma (RCC) has not been reported. The objective of the present study was to examine the preoperative prognostic value of the COP-NLR in patients with localized RCC undergoing nephrectomy.Material and MethodsThe record of 268 patients, who underwent nephrectomy due to a diagnosis of RCC at our institute was analyzed in the study. The cut-off value of platelet count and NLR were defined by receive operating characteristic (ROC) analysis and the areas under the curve (AUC). Patients with both an increased platelet count (> 310×109/l) and an elevated NLR (> 3.85) were assigned to the score 2, and patients with one or neither of these indicators were assigned to the score 1 or 0, respectively. The impact of the COP-NLR and other clinicopathological characteristics on overall survival (OS) and recurrence-free survival (RFS) were evaluated using the univariate and multivariate Cox regression analysis.ResultThe median follow-up duration after surgical resection was 60 months. Multivariate analysis using the 10 clinicopathological findings selected by univariate analyses demonstrated that the preoperative COP-NLR was an independent prognostic factor for OS (HR: 2.32, 95%CI: 1.22 to 4.26, p=0.011) and RFS (HR: 1.91, 95%CI: 1.02 to 3.53, p=0.044).ConclusionThe findings of the current study suggested that the preoperative COP-NLR is an independent prognostic indicator of OS and RFS for patients with localized RCC.

The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma

“…PLT can release growth factors (PLT-derived growth factor, PLT factor, transforming growth factor beta, vascular endothelial growth factor), which may stimulate tumor growth and angiogenesis [16]. The combination of PLT count and NLR has been shown to be an independent prognostic indicator of OS and recurrence-free survival (RFS) for patients with localized RCC [17]. …”

C‐reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma

“…In the molecular‐targeted therapy era, the IMDC risk classification is a standard risk‐based stratification . Whereas the IMDC classification includes inflammatory markers, such as neutrophil and platelet count, several studies have suggested that systemic inflammation measured by NLR and CRP also plays a key role in prognosis in mRCC . Recently, the CAR, a novel inflammation‐based prognostic score, has shown outstanding prognostic value in several cancers .…”

“…12,13 Whereas the IMDC classification includes inflammatory markers, such as neutrophil and platelet count, several studies have suggested that systemic inflammation measured by NLR and CRP also plays a key role in prognosis in mRCC. [14][15][16] Recently, the CAR, a novel inflammation-based prognostic score, has shown outstanding prognostic value in several cancers. [17][18][19] However, only a few studies investigated the impact of CAR on prognosis in patients with mRCC, and no study compared the effect of CAR with the mGPS on prognosis in mRCC.…”

Investigation of the Relationship between Markers of Systemic Inflammatory Response and Head and Neck Tumor Characteristics

“…4–6 Recently, the COP-NLR has been described as a prognostic indicator as well. 7, 8, 13 The COP-NLR system was originally developed to combine the inflammatory data from the NLR and information from reactive thrombocytosis in the platelet count. Building on the previous work by Nakayama, this study sought to find out if the COP-NLR was prognostic in a wide variety of HNCs in various stages.…”

“…Recently, the combination of platelet count to neutrophil-lymphocyte ratio (COP-NLR) has been reported as a prognostic indicator in head and neck cancer 7 and other sites. 8 The study by Nakayama reported only in patients with advanced disease (Stage 3 and Stage 4 disease). Another finding in their paper was that the modified COP-NLR was a better prognostic model than the other COP-NLR models, the 4-group COP-NLR model and the Original COP-NLR model.…”